title: Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.
abstract: Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Antonin
authors.initials: A
authors.lastname: Levy
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guy
authors.forename: Yacine
authors.initials: Y
authors.lastname: Merrouche
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Spano
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D019380:Anti-HIV Agents; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: AIDS,; Bevacizumab,; Targeted therapies,; Toxicity